Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Renal Drug Excretion: Tubular Secretion

Renal Drug Excretion: Tubular Secretion

Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...

Renal Failure: Dose Adjustments

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...

Pharmacokinetics: Drug–Drug Interactions

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023

Same author

Tamoxifen in breast cancer: symptom reporting.

The breast journal·2001

Same author

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1998

Same author

Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1997

Same author

The effect of body mass index and oestrogen receptor level on survival of breast cancer patients.

International journal of epidemiology·1997

Same author

Rate of death from cervical cancer among native Indian women in British Columbia.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne·1992

Search research articles

Related Experiment Video

Updated: Jul 24, 2026

Cell-based Calcium Assay for Medium to High Throughput Screening of TRP Channel Functions using FlexStation 3

Cell-based Calcium Assay for Medium to High Throughput Screening of TRP Channel Functions using FlexStation 3

Published on: August 17, 2011

Probenecid and rifampicin serum levels

R J Fallon, A W Lees, G W Allan

Lancet (London, England)

|October 25, 1975

Summary

Probenecid does not effectively increase serum rifampicin levels when used with a reduced dose. Therefore, probenecid should not be utilized to lower rifampicin dosage in tuberculosis treatment.

Area of Science:

Pharmacology
Infectious Diseases
Clinical Therapeutics

Background:

Rifampicin is a cornerstone medication for tuberculosis treatment.
Optimizing rifampicin dosage and serum levels is crucial for effective therapy and preventing drug resistance.
Investigating methods to manage rifampicin dosage and patient adherence is an ongoing area of research.

Purpose of the Study:

To evaluate the impact of probenecid on serum rifampicin concentrations.
To determine if probenecid can facilitate a reduced rifampicin dosage in antituberculosis therapy.

Main Methods:

Serum rifampicin levels were measured in patients undergoing antituberculosis therapy.
A cohort received a standard 600 mg dose of rifampicin.
Another cohort received a reduced 300 mg dose of rifampicin, pre-administered with 2 g of probenecid.

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Related Experiment Videos

Last Updated: Jul 24, 2026

Cell-based Calcium Assay for Medium to High Throughput Screening of TRP Channel Functions using FlexStation 3

Cell-based Calcium Assay for Medium to High Throughput Screening of TRP Channel Functions using FlexStation 3

Published on: August 17, 2011

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Main Results:

Administering 2 g of probenecid 30 minutes prior to a 300 mg dose of rifampicin did not achieve therapeutic serum levels.
The resulting serum concentrations were less than half of those obtained with the standard 600 mg rifampicin dose.
This indicates a limited efficacy of probenecid in augmenting rifampicin bioavailability at reduced doses.

Conclusions:

Probenecid is not an effective adjunct for reducing rifampicin dosage in antituberculosis regimens.
The use of probenecid in conjunction with a lower dose of rifampicin does not yield adequate serum concentrations for effective treatment.
Clinical guidelines should not recommend probenecid as a strategy to decrease rifampicin dosage due to insufficient efficacy.